<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02291718</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00048275</org_study_id>
    <nct_id>NCT02291718</nct_id>
  </id_info>
  <brief_title>Thoracoabdominal Arortic CTA Study</brief_title>
  <official_title>Comparison of High Iodine Concentration Contrast Material (Isovue 370) vs Standard Protocol (Isovue 300) in Thoracoabdominal Aortic Computed Tomographic Angiography (CTA) for Radiation Dose Reduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the contrast agents and imaging techniques used for
      thoracoabdominal aortic imaging in CT. Imaging parameters and contrast volume are changed and
      adjusted based on the contrast agent, since contrast agents have varying iodine
      concentrations. If the contrast iodine concentration is higher, it may be possible to adjust
      the imaging parameters and lower the overall radiation dose to the patient.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiation Dose</measure>
    <time_frame>30 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Signal to Noise Ratio</measure>
    <time_frame>30 minutes</time_frame>
    <description>Calculated as the ratio of mean attenuation values divided by the standard deviation of attenuation values gathered using a circular region of interest in the thoracic aorta.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hounsfield Unit Attenuation Values</measure>
    <time_frame>30 minutes</time_frame>
    <description>Grayscale values on CT scans are given as Hounsfield units. These Hounsfield units reflect the attenuation of x-ray beams traversing the aortic lumen. We will use Hounsfield units to assess whether the tool contrast agents achieve similar attenuation characteristics essential for diagnosing aortic abnormalities. We will use circular regions of interest in the thoracic aorta to extract the Hounsfield unit measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in Contrast for the Entire Vascular System (coV)</measure>
    <time_frame>30 minutes</time_frame>
    <description>The change in contrast was measured at the proximal segment of the aorta and at the Iliac arteries for each subject.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Thoracic Aortic Aneurysm</condition>
  <arm_group>
    <arm_group_label>Isovue 300 75mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Isovue 300 75mL injected 120 kVp 250 mAs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isovue 370 75mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Isovue 370 75mL injected 100 kVp 240 mAs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isovue 370 60mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Isovue 370 60mL injected 100 kVp 240 mAs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isovue</intervention_name>
    <description>iodine contrast</description>
    <arm_group_label>Isovue 300 75mL</arm_group_label>
    <arm_group_label>Isovue 370 75mL</arm_group_label>
    <arm_group_label>Isovue 370 60mL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing thoracoabdominal aortic (TAA) CTA

          -  Able to provide informed consent

          -  Body Mass Index (BMI) equal to or less than 30

        Exclusion Criteria:

          -  Creatinine greater than 2.0

          -  Allergy to contrast media

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2014</study_first_submitted>
  <study_first_submitted_qc>November 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2014</study_first_posted>
  <results_first_submitted>September 28, 2016</results_first_submitted>
  <results_first_submitted_qc>January 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 24, 2017</results_first_posted>
  <last_update_submitted>March 22, 2017</last_update_submitted>
  <last_update_submitted_qc>March 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Suspected or confirmed</keyword>
  <keyword>TAA</keyword>
  <keyword>Computed tomography angiography</keyword>
  <keyword>CTA</keyword>
  <keyword>Contrast agent</keyword>
  <keyword>Radiation dose</keyword>
  <keyword>Thoracoabdominal aortic aneurysm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Thoracic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Isovue 300 (75mL)</title>
          <description>75mL Isovue 300 injected 120kvp, 250mAs used to obtain CT scan</description>
        </group>
        <group group_id="P2">
          <title>Isovue 370 (75mL)</title>
          <description>75mL Isovue 370 injected 100 kVp, 250 mAs used for obtaining CT</description>
        </group>
        <group group_id="P3">
          <title>Isovue 370 (60mL)</title>
          <description>60mL Isovue 370 injected 100 kVp, 240 mAs used to obtain CT</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Isovue 300 (75mL)</title>
          <description>75mL Isovue 300 injected 120kvp, 250mAs used to obtain CT scan</description>
        </group>
        <group group_id="B2">
          <title>Isovue 370 (75mL)</title>
          <description>75mL Isovue 370 injected 100 kVp, 250 mAs used for obtaining CT</description>
        </group>
        <group group_id="B3">
          <title>Isovue 370 (60mL)</title>
          <description>60mL Isovue 370 injected 100 kVp, 240 mAs used to obtain CT</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="50"/>
            <count group_id="B4" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Radiation Dose</title>
        <time_frame>30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Isovue 300 75mL</title>
            <description>Isovue 300 75mL injected 120 kVp 250 mAs
Isovue: iodine contrast</description>
          </group>
          <group group_id="O2">
            <title>Isovue 370 75mL</title>
            <description>Isovue 370 75mL injected 100 kVp 240 mAs
Isovue: iodine contrast</description>
          </group>
          <group group_id="O3">
            <title>Isovue 370 60mL</title>
            <description>Isovue 370 60mL injected 100 kVp 240 mAs
Isovue: iodine contrast</description>
          </group>
        </group_list>
        <measure>
          <title>Radiation Dose</title>
          <units>mSv</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1" spread="6.2"/>
                    <measurement group_id="O2" value="25.4" spread="5.3"/>
                    <measurement group_id="O3" value="25.5" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Signal to Noise Ratio</title>
        <description>Calculated as the ratio of mean attenuation values divided by the standard deviation of attenuation values gathered using a circular region of interest in the thoracic aorta.</description>
        <time_frame>30 minutes</time_frame>
        <population>Hiatus region of each subject group</population>
        <group_list>
          <group group_id="O1">
            <title>Isovue 300 75mL</title>
            <description>Isovue 300 75mL injected 120 kVp 250 mAs
Isovue: iodine contrast</description>
          </group>
          <group group_id="O2">
            <title>Isovue 370 75mL</title>
            <description>Isovue 370 75mL injected 100 kVp 240 mAs
Isovue: iodine contrast</description>
          </group>
          <group group_id="O3">
            <title>Isovue 370 60mL</title>
            <description>Isovue 370 60mL injected 100 kVp 240 mAs
Isovue: iodine contrast</description>
          </group>
        </group_list>
        <measure>
          <title>Signal to Noise Ratio</title>
          <description>Calculated as the ratio of mean attenuation values divided by the standard deviation of attenuation values gathered using a circular region of interest in the thoracic aorta.</description>
          <population>Hiatus region of each subject group</population>
          <units>Signal-to-Noise Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" spread="4.8"/>
                    <measurement group_id="O2" value="11.8" spread="3.5"/>
                    <measurement group_id="O3" value="13.8" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hounsfield Unit Attenuation Values</title>
        <description>Grayscale values on CT scans are given as Hounsfield units. These Hounsfield units reflect the attenuation of x-ray beams traversing the aortic lumen. We will use Hounsfield units to assess whether the tool contrast agents achieve similar attenuation characteristics essential for diagnosing aortic abnormalities. We will use circular regions of interest in the thoracic aorta to extract the Hounsfield unit measurements.</description>
        <time_frame>30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Isovue 300 75mL</title>
            <description>Isovue 300 75mL injected 120 kVp 250 mAs
Isovue: iodine contrast</description>
          </group>
          <group group_id="O2">
            <title>Isovue 370 75mL</title>
            <description>Isovue 370 75mL injected 100 kVp 240 mAs
Isovue: iodine contrast</description>
          </group>
          <group group_id="O3">
            <title>Isovue 370 60mL</title>
            <description>Isovue 370 60mL injected 100 kVp 240 mAs
Isovue: iodine contrast</description>
          </group>
        </group_list>
        <measure>
          <title>Hounsfield Unit Attenuation Values</title>
          <description>Grayscale values on CT scans are given as Hounsfield units. These Hounsfield units reflect the attenuation of x-ray beams traversing the aortic lumen. We will use Hounsfield units to assess whether the tool contrast agents achieve similar attenuation characteristics essential for diagnosing aortic abnormalities. We will use circular regions of interest in the thoracic aorta to extract the Hounsfield unit measurements.</description>
          <units>Hounsfield units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="289.7" spread="23.8"/>
                    <measurement group_id="O2" value="400.9" spread="31.1"/>
                    <measurement group_id="O3" value="393.9" spread="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Variation in Contrast for the Entire Vascular System (coV)</title>
        <description>The change in contrast was measured at the proximal segment of the aorta and at the Iliac arteries for each subject.</description>
        <time_frame>30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Isovue 300 75mL</title>
            <description>Isovue 300 75mL injected 120 kVp 250 mAs
Isovue: iodine contrast</description>
          </group>
          <group group_id="O2">
            <title>Isovue 370 75mL</title>
            <description>Isovue 370 75mL injected 100 kVp 240 mAs
Isovue: iodine contrast</description>
          </group>
          <group group_id="O3">
            <title>Isovue 370 60mL</title>
            <description>Isovue 370 60mL injected 100 kVp 240 mAs
Isovue: iodine contrast</description>
          </group>
        </group_list>
        <measure>
          <title>Variation in Contrast for the Entire Vascular System (coV)</title>
          <description>The change in contrast was measured at the proximal segment of the aorta and at the Iliac arteries for each subject.</description>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.113" spread="0.073"/>
                    <measurement group_id="O2" value="0.124" spread="0.063"/>
                    <measurement group_id="O3" value="0.107" spread="0.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Isovue 300 (75mL)</title>
          <description>75mL Isovue 300 injected 120kvp, 250mAs used to obtain CT scan</description>
        </group>
        <group group_id="E2">
          <title>Isovue 370 (75mL)</title>
          <description>75mL Isovue 370 injected 100 kVp, 250 mAs used for obtaining CT</description>
        </group>
        <group group_id="E3">
          <title>Isovue 370 (60mL)</title>
          <description>60mL Isovue 370 injected 100 kVp, 240 mAs used to obtain CT</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Lynne Koweek</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-684-8111</phone>
      <email>lynne.koweek@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

